Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses
The novel coronavirus SARS-CoV-2 is damaging the world’s social and economic fabrics seriously. Effective drugs are urgently needed to decrease the high mortality rate of COVID-19 patients. Unfortunately, effective antiviral drugs or vaccines are currently unavailable. Herein, we systematically eval...
Main Authors: | Guobing Li, Shasha Ruan, Xiaolu Zhao, Qi Liu, Yali Dou, Fengbiao Mao |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Computational and Structural Biotechnology Journal |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2001037020305237 |
Similar Items
-
Network bioinformatics analysis provides insight into drug repurposing for COVID-19
by: Xu Li, et al.
Published: (2021-06-01) -
Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics
by: Dan-Yang Liu, et al.
Published: (2021-04-01) -
Identification of candidate repurposable drugs to combat COVID-19 using a signature-based approach
by: Sinead M. O’Donovan, et al.
Published: (2021-02-01) -
Insights into bioinformatic approaches for repurposing compounds as anti-viral drugs
by: Wenxiao Zheng, et al.
Published: (2021-08-01) -
Enhancement of the IFN-β-induced host signature informs repurposed drugs for COVID-19
by: Chen-Tsung Huang, et al.
Published: (2020-12-01)